Vaxart Announces Publication Of Preclinical Study Results Evaluating Its Oral Mucosal Vaccine Platform Against Highly Pathogenic Avian Influenza H5N1; Candidate VXA-H5-02 Induced Robust Cross-Neutralizing Antibodies

Vaxart has published positive preclinical study results for its oral mucosal vaccine candidate VXA-H5-02 against Highly Pathogenic Avian Influenza H5N1, demonstrating a 100% survival rate in immunized ferrets following a lethal challenge. The study, published in Frontiers in Immunology, highlighted significant reductions in viral load and shedding, as well as robust mucosal and systemic antibody responses. VXA-H5-02 also showed cross-neutralizing activity against various H5 strains, indicating potential for broader protection.